Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018954 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00018954 is a Phase 2 study that has completed, run by National Institutes of Health Clinical Center (CC).
The verdict
NCT00018954, a Phase 2 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of two treatment regimens for patients in developing countries with diffuse non-Hodgkin's lymphoma and acute lymphoblastic leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-10 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018954
The ClinicalTrials.gov registry entry for NCT00018954 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00018954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018954 about?
NCT00018954 is a clinical study titled "Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of two treatment regimens for patients in developing countries with diff...
What is the current status of trial NCT00018954?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-10. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00018954?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin hydrochloride (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00018954?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.